logo
Plus   Neg
Share
Email

Novartis : Type 2 Diabetes Study Shows Long-term Clinical Benefits

Novartis (NVS) said that five-year VERIFY study in type 2 diabetes demonstrated long-term clinical benefits of early combination treatment with Galvus and metformin.

The company noted that early combination treatment strategy with vildagliptin (Galvus) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients.

The company said it is committed to optimizing patient management of type 2 diabetes to achieve better glycemic control and favorable long-term clinical outcomes.

Additional pre-defined secondary analyses of the VERIFY study results are ongoing and data will be disclosed over the coming months at international and local medical congresses and in scientific journals, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
European Union has ordered Broadcom (AVG) to stop applying certain exclusivity agreements with six of its main customers. According to European Union, this will prevent serious and irreparable harm to competition likely to be caused by Broadcom's conduct. In June, the European Commission opened... Amazon.com Inc. (AMZN) announced that it will live stream behind the scenes of its Robotics Fulfillment Center to for students pursuing STEM and Computer Science education. Amazon said on Thursday, October 17 at 7:00 p.m. ET / 4:00 p.m. PT, teachers and students can go online to Twitch to watch and... Walmart has rolled back prices on more than 200 additional toys in stores and online as it braces for the upcoming holiday season. The retail giant is now offering more than 400 toys at a special price, thanks to its already existing rollbacks on toys. In August, Walmart unveiled its list of top-rated toys for 2019 that were selected by kids.
Follow RTT
>